United Therapeutics Chairperson & CEO Martine Rothblatt Sells $5.59M in Shares Under 10b5-1 Plan
UNITED THERAPEUTICS Corp
Subscribe to track UTHR
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
# Insider Transaction Alert: United Therapeutics Corp (UTHR)
**Insider:** ROTHBLATT MARTINE A (Chairperson & CEO, Director)
**Date of Transaction:** 2026-10-26
**Filing Date:** 2026-10-27
### Transaction Summary
- **Action:** Option Exercise & Sale (Rule 10b5-1 Plan)
- **Shares Sold:** 9,500 shares
- **Average Price:** ~$588.64 (Range: $585.01 - $593.09)
- **Total Gross Proceeds:** $5,592,094.27
- **Exercise Price:** $117.76 (9,500 options exercised)
- **Net Proceeds:** ~$4,473,374.27
### Post-Transaction Holdings
- **Beneficially Owned (This Trust):** 324,443 shares
- **Total Direct & Indirect Stock Held:** 668,728 shares
- **Derivative Securities (Options Remaining):** 157,410 options
Comprehensive Analysis
Overview & Context
On October 27, 2026, Martine A. Rothblatt, Chairperson and CEO of United Therapeutics Corp (UTHR), filed a Form 4 detailing the exercise of stock options and concurrent sale of common stock totaling $5,592,094.27 on October 26, 2026.
Transaction Breakdown
- Option Exercise: Dr. Rothblatt exercised 9,500 stock options with an exercise price of $117.76 per share (expiring March 15, 2027).
- Open Market Sales: The 9,500 underlying common shares were sold in eight tranches at weighted average prices ranging from $585.71 to $592.92, achieving an aggregate weighted average price of approximately $588.64 per share.
- Pre-Arranged Plan: All transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on November 7, 2025. The plan covers up to 1,734,410 options expiring March 15, 2027, or concludes on December 31, 2026.
Holdings & Position Assessment
Following these transactions:
- The specific family trust holds 324,443 shares of common stock and 157,410 stock options.
- Across all direct and indirect holdings (including personal holdings, spouse holdings, and various family trusts), Dr. Rothblatt continues to beneficially control over 668,000 shares of common stock in addition to remaining option grants.
Significance
Because these trades were executed systematically under a scheduled Rule 10b5-1 plan to exercise expiring options, this activity is categorized as Low informational significance and does not suggest a discretionary shift in management sentiment.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.